Advertisement
U.S. markets closed

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.7491-0.0077 (-1.02%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.7568
Open0.7321
Bid0.7309 x 100
Ask0.8311 x 100
Day's Range0.7200 - 0.7600
52 Week Range0.6500 - 2.3700
Volume14,547
Avg. Volume50,665
Market Cap144.14M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.3800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.91
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DBVT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • DBV Technologies S.A.
    Daily – Vickers Top Buyers & Sellers for 02/12/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Insider Monkey

    DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript

    DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript March 7, 2024 DBV Technologies S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results […]

  • GlobeNewswire

    DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

    Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K wi

  • GlobeNewswire

    DBV Technologies Reports Full Year 2023 Financial Results and Business Update

    Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Strengthened executive leadership team in preparation for BLA submissionReported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa